Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LMRI vs LBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LBRX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–0 Matrix Metrics)

LBRX Overall Winner 6-Pillar Tally: LMRI 0 – 4 LBRX (2 Tie) Matrix Metrics: LMRI 0 – 8 LBRX

As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LMRI carries a Unified Composite Score of 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin), whereas LBRX carries 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LMRI (32.1/100 SELL) and LBRX (38.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile LBRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LMRI vs LBRX
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73
LBRX NASDAQ Head-to-Head Winner
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$38.85
-2.97% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 60% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 20.0 Fund 36.0 Flow 54.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -6.4%) with fading momentum, RSI 44
RSI-14: 43.8 · SMA20: $41.07 · SMA50: $39.49

6-Pillar Scorecard Institutional Category Breakdown (LMRI 0 – 4 LBRX)

Columns: Metric · LMRI · LBRX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale LBRX
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $1.3B
3. Profitability & Quality LBRX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -38.8%
4. Balance Sheet & Cash Flow LBRX
Cash Generation (TTM) N/A -$144M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $210M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LBRX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 78.9% (4th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LMRI (0) vs LBRX (8)
Institutional Metric LMRI LBRX Criterion Row Edge
Market Capitalization
Scale
N/A $1.3B Larger Scale LBRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth LBRX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin LBRX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin LBRX
Return on Equity (ROE)
Capital Efficiency
N/A -38.8% Higher ROE LBRX
52-Week Range Position
Momentum
60% ($6–$19) 68% ($15–$50) Stronger Trend LBRX
Beta / 30D Volatility
Risk Regime
1.22β · 85% Vol 1.07β · 60% Vol Lower Realized Risk LBRX
Unified Institutional Score
Composite Signal
32.1 / 100 (SELL) 38.2 / 100 (SELL) Higher Composite LBRX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$144M ($210M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +32.4 pp
LMRI: +30.95% · LBRX: -1.45%
3M Horizon LMRI +39.76 pp
LMRI: +20.34% · LBRX: -19.42%
6M Horizon LMRI +40.09 pp
LMRI: +78.25% · LBRX: +38.16%
1Y Horizon LBRX +115.04 pp
LMRI: -23.0% · LBRX: +92.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs LBRX. Trailing 12-month operating profitability (LMRI N/A vs LBRX 0.0%) and valuation multiples (LMRI N/M vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-38.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LBRX CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 78.9%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact LBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LMRI vs LBRX Key Questions & Quantitative Answers

As of Nov 20, 2026, LB Pharmaceuticals Inc (LBRX) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LMRI carries a Unified Composite Score of 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin), whereas LBRX carries 38.2/100 (SELL) at $38.85 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although LBRX compares more favorably head-to-head, both LMRI (32.1/100 SELL) and LBRX (38.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile LBRX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LBRX leads the Growth & Scale pillar: LMRI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LMRI generates N/A in USD-normalized revenue versus N/A for LBRX. In operating R&D and SG&A reinvestment, LMRI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LBRX.

LMRI and LBRX trade at balanced relative valuation multiples. LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LMRI (N/A ROE) versus LBRX (-38.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk). By comparison, LBRX carries 78.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.